Literature DB >> 18774962

Increased activated Akt expression in renal cell carcinomas and prognosis.

Martina Hager1, Heike Haufe1, Ralf Kemmerling1, Wolfgang Hitzl2, Gregor Mikuz3, Patrizia L Moser3, Christian Kolbitsch4.   

Abstract

Renal carcinogenesis is promoted by overexpression of the activated serine/ threonine kinase Akt (p-Akt) and supposedly a concomitant reduction in phosphatase and tensin homologue deleted on chromosome 10 tumour suppressor gene (PTEN), which normally inhibits the activation of Akt. Because promising anti-cancer therapies increasingly focus on pathways involving p-Akt and PTEN, the present study evaluated the expression of p-Akt in renal cell carcinomas and compared it with prognosis. P-Akt and PTEN expression were analysed in a tissue microarray (TMA) from renal cell carcinoma (n = 386) and adjacent uninvolved renal tissue (n = 32) specimens. Increased p-Akt was found more often in the nucleus than in the cytoplasm, and PTEN was concomitantly reduced in about 50% of cases. Neither tumour grade nor stage influenced p-Akt expression, whereas the clear cell and papillary subtypes showed increased p-Akt more often than did the chromophobe or sarcomatoid types. Increased cytoplasmic and nuclear p-Akt levels were independent prognostic factors for diminishing patient survival. The present study found significantly increased nuclear but also cytoplasmic p-Akt expression in renal cell carcinoma subtypes. Increased nuclear and cytoplasmic p-Akt was an independent prognostic factor for diminishing patient survival. The considerable number of high-grade and high-stage RCC showing increased p-Akt and reduced PTEN would justify further evaluation of therapeutic concepts based on inhibitors of the PI3K/p-Akt/mTOR pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18774962      PMCID: PMC6512376          DOI: 10.1111/j.1582-4934.2008.00488.x

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  20 in total

1.  A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

Authors:  E Jonasch; E Hasanov; P G Corn; T Moss; K R Shaw; S Stovall; V Marcott; B Gan; S Bird; X Wang; K A Do; P F Altamirano; A J Zurita; L A Doyle; P N Lara; N M Tannir
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

Review 2.  Metformin and cancer.

Authors:  Natalia G Vallianou; Angelos Evangelopoulos; Christos Kazazis
Journal:  Rev Diabet Stud       Date:  2014-02-10

Review 3.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

4.  Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.

Authors:  Liling Zeng; Ming Bai; Amit K Mittal; Wassim El-Jouni; Jing Zhou; David M Cohen; Mina I Zhou; Herbert T Cohen
Journal:  Cancer Res       Date:  2013-07-01       Impact factor: 12.701

5.  p-AKT overexpression in primary renal cell carcinomas and their metastases.

Authors:  Martina Hager; Heike Haufe; Lukas Lusuardi; Nikolaus Schmeller; Christian Kolbitsch
Journal:  Clin Exp Metastasis       Date:  2010-09-16       Impact factor: 5.150

6.  AMPK as a therapeutic target in renal cell carcinoma.

Authors:  Jennifer Woodard; Sonali Joshi; Benoit Viollet; Nissim Hay; Leonidas C Platanias
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

Review 7.  New Insights into Protein Hydroxylation and Its Important Role in Human Diseases.

Authors:  Giada Zurlo; Jianping Guo; Mamoru Takada; Wenyi Wei; Qing Zhang
Journal:  Biochim Biophys Acta       Date:  2016-09-20

8.  pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner.

Authors:  Jianping Guo; Abhishek A Chakraborty; Pengda Liu; Wenjian Gan; Xingnan Zheng; Hiroyuki Inuzuka; Bin Wang; Jinfang Zhang; Linli Zhang; Min Yuan; Jesse Novak; Jin Q Cheng; Alex Toker; Sabina Signoretti; Qing Zhang; John M Asara; William G Kaelin; Wenyi Wei
Journal:  Science       Date:  2016-08-26       Impact factor: 47.728

9.  Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma.

Authors:  Zachary S Morris; Andrea I McClatchey
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-01       Impact factor: 11.205

10.  Phosphorylated AKT expression in tumor-adjacent normal tissue is associated with poor prognosis in patients with hepatocellular carcinoma.

Authors:  Yao-Li Chen; Po-Ming Chen; Ying-Zi Ming; Ping-Yi Lin; Chih-Ping Chu; Pei-Yi Chu
Journal:  Oncol Lett       Date:  2017-10-04       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.